P I Industries Ltd Q1 FY2027 Concall Summary

Key Takeaways

• A challenged quarter, but a confident long-game: Domestic agri volume grew 12% while revenue rose only 3%, and exports stayed soft, yet management remains positive on FY27 growth and calls FY27 "better over FY26."
• The innovation pipeline is now the story: First India-discovered NCE insecticide Pioxaniliprole is set for domestic launch, the nematicide is registered in Brazil, Mexico and the US, and 4-5 AgChem molecules are slated for FY27 launch.
• Subsidiary losses are deliberate, not accidental: ~₹100 crore EBITDA loss this quarter, largely from global Biologics, is framed as front-loaded investment in technologies and market development that will scale into revenue.
• Margins are being squeezed from both sides: Gross margin held at 57%, but input costs and selling-price pressure create a "fine balance" challenge across the industry.
• What to watch next quarter: Whether Pioxaniliprole actually launches domestically, whether export recovery materializes in H2 as guided, and whether the Biologics investment phase starts converting into disclosed revenue.

Demand Environment & Pricing

• Domestic agri started weak, then recovered: El Nino, heatwaves, delayed sowing and high prior-year inventories hit pre-placement and chemical sales early in Q1. Sowing and monsoon have since picked up and are at par with last year.
• Volume is up, price is down: 12% domestic volume growth translated into only 3% revenue growth, a clear signal of pricing pressure. Management says its approach is to push market share with products rather than chase price softening.
• Exports remain the hard part: Soft commodity prices, the previous year's industry downturn, muted crop economics and consumption patterns all pressure growth and pricing. Geopolitical uncertainties, genericization and tariffs add cost on top.
• The squeeze is structural this cycle: Input costs are elevated while selling prices stay weak, and management notes global companies' CAGRs reflect the same challenge on both fronts.

Mayank Singhal: "So striking that fine balance is a challenge in the industry today. And you can see that from the CAGRs of the global companies which are facing this challenge, both on the input and selling price fronts."

Innovation Pipeline & New Products

• Pioxaniliprole is the flagship: PI's first NCE insecticide, discovered in India, is in advanced stages for domestic launch, awaiting regulatory approvals. Management expects an early start this year, hoping within the year for India.
• Global rollout is sequenced: Registration has started in other geographies, with one geography coming up next year and one the year after. Management is also driving dialogues for partnerships at global footprint.
• Nematicide is already in the field: Registered in Brazil, Mexico and the US, with the US "basically just getting launched." Brazilian farmers planted roughly 0.5 crore hectares with the product last season and feedback is very positive.
• Nematicide ambition is explicit: Management says it is chasing something "not less than three digits in millions of dollars" in peak sales potential, and that double-digit market share in Brazil "is not a challenge."
• Dicloromezotiaz adds another launch: Registered for diamondback moth, this is the first commercial launch in the Indian context and part of three to four products launching this coming season. Management expects it to become a three-digit product over five to seven years.
• Biologicals are scaling: Two products launched, another two to three in the pipeline, and the business achieved 50% growth this quarter despite fertilizer shortages.

Mayank Singhal: "Our first NCE, Pioxaniliprole, an insecticide, discovered in India, for Indian farmers and now to go to global farmers is set to launch in the domestic market very soon awaiting regulatory approvals."

Subsidiary Losses & Investment Phase

• The headline loss is deliberate: ~₹100 crore EBITDA loss in subsidiaries this quarter is largely from the Biologics business. Last year's global Biologics EBITDA loss was ₹120 crore.
• Management calls them "good losses": The spending is on front-loaded investments in new technologies, capabilities and market development, including 1,000 farmer interactions and 500 demonstrations globally. These soft investments hit the P&L as expenses today to create future business.
• Pharma adds volatility: A few order book items got delayed to the next delivery schedule. Management is candid that the early-stage CRDMO portfolio is small, so volatility is higher until scale, customers and portfolios expand.
• R&D is non-negotiable: R&D expenses have risen from ₹100 crore to ₹400 crore plus over three to four years. Management frames this as value creation, not loss, and intends to remain at 3% to 4% of revenues invested into research.

Mayank Singhal: "You may call it good losses, which is equated to investing and in my view because you are building investments to create business for the future."

Pharma & CRDMO

• Early signs of transformation: Management sees positive signs of PI becoming a differentiated CRDMO organization, with a couple of interesting queries expected to lead to commercial phase. The long-term ambition is a fully integrated CRDMO platform.
• Integrated drug discovery partnership locked: PI signed as exclusive partner for integrated drug discovery with a biotech. Bandwidth exists for two to three more such products, and management is evaluating two to three different opportunities.
• Guidance is maintained: Pharma business guidance given earlier is unchanged. Revenue gets securitized unless products shift quarter-to-quarter or demand shifts based on launches.
• Volatility is acknowledged: Management is honest that the early-stage portfolio is small and volatile, and that the CRDMO model is a long-gestation J-curve requiring patience, capability building and customer trust.

Mayank Singhal: "We are in the early stages, and have more volatility, to be very honest, because our portfolio levels are very small. The minute we scale, and more customers and portfolios expand, the volatility, standard deviation reduces."

Electronic Chemicals & New Verticals

• Still small, but commercial now: Management admits electronic chemicals are "not substantial" and have a longer gestation. A commercial plant is now in operations and commercial supplies have started with new technology.
• The ambition is large: Management says it is "trying to get into a billion dollar play" and is investing in a very high-tech manufacturing asset to support next-generation technologies, avoiding the commoditized lower end of the value chain.
• Flow chemistry plant commissioned: One of the world's largest flow plants is now operational, with advanced flow chemistry capabilities for better, sustainable, safer handling and superior process control and cost efficiency.
• Capex is spread across three verticals: ₹250 crore Q1 capex went into existing manufacturing assets, new verticals, and innovation-led approaches in geographies and products. Full-year guidance is ₹700-₹800 crore.

Mayank Singhal: "We are trying to get into a billion dollar play, but significant from our perspective to have entered that space."

Margins & Working Capital

• Gross margin held at 57%: Supported by disciplined execution, with volatility in raw material prices being closely monitored.
• The margin objective is defensive: Management's objective is to keep and sustain gross margins at best possible levels by optimizing and being agile given the volatile world. Product mix optimization is not the only answer.
• Working capital improved materially: The team delivered a 19-day reduction in net working capital, releasing ₹300 crore cash despite the challenging environment.
• Currency is not the story: Management says the business is a pass-through model of value proposition, currency benefits are shared, and currency risk management is in play. The business is about product and margins, not currencies.

Mayank Singhal: "Our business is not about currencies, but our business is more about the product and margins that you want to sustain."

Guidance & Commitments

Key Metrics